| Novartis Terminates Combination Therapies, Studies With Rasilez/Tekturna - NASDAQ |
|
|
NASDAQ (RTTNews.com) - Novartis AG (NVS) Tuesday said it has terminated ALTITUDE study with Rasilez/Tekturna in high-risk patients with diabetes and renal impairment, as an independent data monitoring committee identified higher adverse events in patients ... Novartis announces termination of ALTITUDE study with Rasilez®/ Tekturna® in |